MediWound (MDWD) Stock Price, News & Analysis

Company Overview

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Key Stats

• Today's Range: $17.61 to $18.84
• 50-Day Range: $16.01 to $20.33
• 52-Week Range: $12.78 to $24.00
• Volume: 23,348 shs
• Average Volume: 62,596 shs
• Market Capitalization: $191.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.50
• Consensus Rating: Buy

MediWound Stock Analysis - MarketRank™

MediWound scored higher than 23% of companies evaluated by MarketBeat, and ranked 851st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MediWound has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MediWound are expected to grow in the coming year, from ($2.66) to ($2.24) per share.

Price to Book Value per Share Ratio

MediWound has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.35% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently increased by 2.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediWound does not currently pay a dividend.

Dividend Growth

MediWound does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.35% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently increased by 2.96%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MediWound this week, compared to 1 article on an average week.

Search Interest

3 people have searched for MDWD on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MediWound insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of MediWound is held by insiders.

Percentage Held by Institutions

46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDWD Stock Analysis - Frequently Asked Questions

How have MDWD shares performed this year?

MediWound's stock was trading at $17.80 at the start of the year. Since then, MDWD stock has decreased by 0.4% and is now trading at $17.7250.
View the best growth stocks for 2025 here.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) released its earnings results on Tuesday, November, 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.50. MediWound had a negative trailing twelve-month return on equity of 82.17% and a negative net margin of 142.29%.

When did MediWound's stock split?

MediWound shares reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Who are MediWound's major shareholders?

MediWound's top institutional investors include Yelin Lapidot Holdings Management Ltd. (7.89%), Essex Investment Management Co. LLC (1.38%), Northern Trust Corp (1.34%) and Sargent Investment Group LLC (1.12%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/26/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 3/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MDWD
• CUSIP: N/A
• CIK: 1593984
• Web: www.mediwound.com
• Phone: 972779714100
• Fax: 972-77-971-4111
• Employees: 80
• Year Founded: 2001

Price Target and Rating

• Average Stock Price Target: $27.50
• High Stock Price Target: $30.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +55.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,720,000.00
• Net Margins: -142.29%
• Pretax Margin: -141.46%
• Return on Equity: -82.17%
• Return on Assets: -33.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $18.69 million
• Price / Sales: 10.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.43 per share
• Price / Book: 5.17

Miscellaneous

• Outstanding Shares: 10,790,000
• Free Float: 9,794,000
• Market Cap: $191.25 million
• Optionable: Optionable
• Beta: 0.81